AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
Article excerpt
Highlighted: the sentence this signal was extracted from
THOUSAND OAKS, Calif. , Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2026. "Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise," said Robert A. Bradway, chairman and chief executive officer. "The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade." Key results include: References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion. Product Sales Performance General Medicine Rare Disease Inflammation Oncology Established Products Product Sales Detail by Product and Geographic Region $Millions, except percentages Q3 '26 Q3 '25 YOY Δ U.S ROW TOTAL TOTAL TOTAL Repatha ® $ 666 $ 419 $ 1,085 $ 794 37 % EVENITY ® 557 194 751 541 39 % Prolia ® 409 223 632 1,139 (45 %) TEPEZZA ® 441 85 526 560 (6 %) KRYSTEXXA ® 419 - 419 320 31 %...
Keep reading with a free account
The rest of this article, and every signal for Amgen, is in your free account.
